<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014401</url>
  </required_header>
  <id_info>
    <org_study_id>36928</org_study_id>
    <nct_id>NCT03014401</nct_id>
  </id_info>
  <brief_title>The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis</brief_title>
  <official_title>The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical and functional outcomes of patients with
      mild to moderate arthroscopically confirmed osteoarthritis between the following two groups:

        1. Partial fat pad harvest with Adipose-Derived Stem Cell (ADSC) transplantation with
           standard arthroscopic treatment consisting of: partial meniscectomy, cartilage
           stabilization, loose body removal and selective synovectomy.

        2. Standard arthroscopic treatment (above) with out cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose-derived stem cells (ADSC) may be beneficial to patients with OA because they may
      differentiate into chondrocytes, promote endogenous tissue repair, and have potent
      anti-inflammatory properties.

      Early studies show promising clinical results using ADSCs to treat patients with
      osteoarthritis, but no clinical trials have been completed comparing cellular therapy to
      standard arthroscopic treatment.

      The investigators aim to determine whether ADSC transplantation as adjuvant therapy in
      patients with arthroscopic findings of mild to moderate arthritis will result in improved
      clinical outcomes scores at one and two-year follow-up compared to standard arthroscopic
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative KOOS score 24 months following surgery</measure>
    <time_frame>The study will end after 24 month follow-up is completed in all participants.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tegner score</measure>
    <time_frame>6, 12, 24 months</time_frame>
    <description>Patient reported outcomes measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysholm score</measure>
    <time_frame>6, 12, 24 months</time_frame>
    <description>Patient reported outcomes measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VR-12</measure>
    <time_frame>6, 12, 24 months</time_frame>
    <description>Patient reported outcomes measures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MRI scans -</measure>
    <time_frame>1, 12, 24 months</time_frame>
    <description>Average cartilage thickness. Defect fill (percent) routine clinical sequences, T2, T1p</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic debridement with stem cell transplantation</intervention_name>
    <description>Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.</description>
    <arm_group_label>Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic debridement only</intervention_name>
    <description>standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 35 and 70 years-old

          -  Patient is scheduled to undergo one or a combination of the following procedures:

               -  Meniscal debridement or partial menisectomy

               -  Meniscal repair that does not necessitate a different postoperative protocol from
                  meniscal debridement or partial menisectomy

               -  Removal of loose bodies

               -  Chondroplasty

               -  Synovectomy

               -  Soft tissue releases for flexion or extension contracture.

          -  Diagnosis of pre-existing mild to moderate osteoarthritis of the medial or lateral
             femoral condyle (Kellgren-Lawrence Grade 2 or 3)

          -  &lt; 6 months of knee pain or &lt; 6 months of a significant exacerbation of existing knee
             pain

          -  Physical examination findings consistent with the proposed surgical procedure.

          -  Failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy
             and trial of anti-inflammatory medications, with or without concomitant bracing and/or
             injections

        Exclusion Criteria:

          -  Age &lt; 35 or &gt; 70 years old

          -  Radiographs demonstrating either no, little or severe osteoarthritis
             (Kellgren-Lawrence Grade 0, 1 or 4)

          -  Previous injury or surgery to the infrapatellar fat pad (assessed by MRI)

          -  Patient scheduled to undergo any concomitant surgical procedures with the exception
             of:

               -  Meniscal debridement or partial menisectomy

               -  Meniscal repair that does not necessitate a different postoperative protocol from
                  meniscal debridement or partial menisectomy

               -  Removal of loose bodies

               -  Chondroplasty

               -  Synovectomy

               -  Soft tissue releases for flexion or extension contracture

          -  Prior surgery on ipsilateral knee involving cartilage regeneration (microfracture,
             Autologous Chondrocyte Implantation, etc) or meniscal transplant/implant

          -  Previous arthroscopy within 1 year

          -  Subchondral edema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason L Dragoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Backer</last_name>
    <phone>(650) 721-7653</phone>
    <email>mbacker@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason L Dragoo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jason L. Dragoo</investigator_full_name>
    <investigator_title>Assoc Prof-Med Ctr Line</investigator_title>
  </responsible_party>
  <keyword>stem cell</keyword>
  <keyword>knee pain</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>arthritis</keyword>
  <keyword>ADSC</keyword>
  <keyword>fat stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

